Lenz & Staehelin advised Asceneuron in this transaction. Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron have announced the signing of a licensing…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
